Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK Prime Minister unveils plans to tackle prostate cancer
The funding will be used to carry out prostate cancer studies over the next five years. More than 40,000 men will be recruited in the prostate cancer trials
The funding will be used to carry out prostate cancer studies over the next five years. More than 40,000 men will be recruited in the prostate cancer trials
IONIS-AZ6-2.5-LRx has been designed by the US company to inhibit an undisclosed target for the treatment of patients having nonalcoholic steatohepatitis (NASH). AstraZeneca and Ionis had previously entered
The trail demonstrated that upadacitinib achieved the primary endpoints of ACR20a and clinical remission remissionb against placebo placebo, as well as achieved all ranked secondary endpoints against either
As per the deal that has been approved unanimously by the boards of the two companies, Novartis will pay $218 for each share of AveXis. The deal will
The external data monitoring committee (eDMC) concluded that the pivotal phase 3 Echo-301/Keynote-205 study has failed to achieve the primary endpoint of improving progression-free survival in the overall
Rebiotix has designed microbiota restoration therapy (MRT) drug platform, which aims to deliver healthy, live and human-derived microbes into a sick patient’s intestinal tract to treat disease. The
The company has revealed the top-line results from the phase 3 study of Cyramza as a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC).
Under the deal, the companies will jointly develop OSE-172, which is a SIRP-alpha antagonist targeting myeloid lineage cells. SIRP-alpha is a receptor showed by myeloid lineage cells such
The FDA has accepted AstraZeneca and MedImmune’s biologics license application (BLA) for moxetumomab pasudotox, which is an investigational anti-CD22 recombinant immunotoxin and potential new medicine to treat adult
ALKS 5461 is a proprietary, investigational, once-daily oral medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an